Susquehanna International Group
TRIL

Susquehanna International Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Susquehanna International Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-439,800
Closed -$7.72M – 14457
2021
Q3 		$7.72M Buy
439,800
+350,000
+390% +$4.09M ﹤0.01% 3259
2021
Q2 		$871K Sell
89,800
-99,400
-53% -$935K ﹤0.01% 8155
2021
Q1 		$2.03M Sell
189,200
-209,200
-53% -$2.59M ﹤0.01% 5873
2020
Q4 		$5.86M Buy
398,400
+228,400
+134% +$3.29M ﹤0.01% 3189
2020
Q3 		$2.42M Buy
170,000
+74,300
+78% +$741K ﹤0.01% 4263
2020
Q2 		$774K Buy
95,700
+48,200
+101% +$298K ﹤0.01% 6457
2020
Q1 		$192K Buy
+47,500
New +$180K ﹤0.01% 8748
2018
Q2 		– Sell
-11,400
Closed -$82K – 10730
2018
Q1 		$82K Sell
11,400
-11,900
-51% -$90.2K ﹤0.01% 8779
2017
Q4 		$169K Buy
+23,300
New +$193K ﹤0.01% 8414

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's TRIL Position: Q4 2021 in Review

Susquehanna International Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 379,627 shares — an estimated $6.67M sold.

Susquehanna International Group first reported a position in TRIL in Q3 2016 and held it in 9 quarters. The position peaked at $6.67M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Susquehanna International Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Susquehanna International Group sold 379,627 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $6.67M.
  • Susquehanna International Group first reported a position in Trillium Therapeutics Inc. in Q3 2016 and held it in 9 quarters.
  • Susquehanna International Group's Trillium Therapeutics Inc. position peaked at $6.67M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.